Recalled Abbott Infant Formula
The Recalled Abbott Infant Formula litigation was centralized before Judge Matthew F. Kennelly in the Northern District of Illinois in August 2022, consolidating claims arising from a 2022 recall of certain Abbott powdered infant formula products after reports linked bacterial contamination at a Michigan manufacturing facility to infant illness, and the resulting recall contributed to a widely reported nationwide formula shortage. The consolidated claims combined economic-loss theories tied to the shortage and recall with personal-injury claims alleging that contaminated formula caused illness in infants.
With 14 of 141 total filed actions still pending, the docket has moved through the large majority of its original filing population in roughly three years — a pace consistent with claims that were, for the most part, resolvable through relatively contained factual disputes (a specific recalled lot, a specific facility, a defined illness pattern) rather than a sprawling, open-ended general-causation fight of the kind that characterizes some pharmaceutical mass torts. That structural clarity likely supported faster individual resolution than a docket built around a more contested scientific causation theory.
What remains at this stage is a small population of claims that, by definition, did not resolve along the same timeline as the rest of the docket, and understanding each one's specific posture — the severity of alleged illness, timing relative to the recall, and evidentiary strength — is the central question for assessing its resolution path from here. Criterica Intelligence's platform tracks this kind of contained-causation mass tort pattern, distinguishing dockets that resolve relatively efficiently due to well-defined factual triggers from those where causation itself remains the central open question, across every active MDL. A companion capital brief on this docket is available through Criterica Capital.
A 2022 recall of certain Abbott powdered infant formula products after reports linked bacterial contamination at a Michigan manufacturing facility to infant illness, which also contributed to a nationwide formula shortage that generated related economic-loss claims.
With 14 of 141 total filed actions pending, the docket has moved through most of its claims relatively efficiently, consistent with a factual pattern — a specific recalled lot, facility, and illness profile — that is more contained than an open-ended general-causation dispute.
The specific posture of each claim — severity of alleged illness, timing relative to the recall, and evidentiary strength — since these claims did not resolve along the same timeline as the rest of the docket.
It resolved faster than many pharmaceutical mass torts because its factual triggers — a defined recall, facility, and contamination event — are more contained than an open general-causation fight, a structural distinction Criterica Intelligence tracks across comparable dockets.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.